| Title: |
Population pharmacokinetics of bictegravir in real-world people with HIV |
| Authors: |
Ekobena, Pierre; Briki, Myriam; Dao, Kim; Marzolini, Catia; Andre, Pascal; Buclin, Thierry; Cavassini, Matthias; Guidi, Monia; Thoueille, Paul; Abela, I A; Aebi-Popp, K; Anagnostopoulos, A; Battegay, M; Bernasconi, E; Braun, D L; Bucher, H C; Calmy, A; Cavassini, M; Ciuffi, A; Dollenmaier, G; Egger, M; Elzi, L; Fehr, J S; Fellay, J; Frigerio Malossa, S; Furrer, H; Fux, C A; Günthard, H F; Hachfeld, A; Haerry, D H U; Hasse, B; Hirsch, H H; Hoffmann, M; Hösli, I; Huber, M; Jackson-Perry, D; Kahlert, C R; Keiser, O; Klimkait, T; Kouyos, R D; Kovari, H; Kusejko, K; Labhardt, N D; Leuzinger, K; Martinez de Tejada, B; Marzolini, C; Metzner, K J; Müller, N; Nemeth, J; Nicca, D |
| Source: |
Journal of Antimicrobial Chemotherapy ; volume 80, issue 10, page 2782-2789 ; ISSN 0305-7453 1460-2091 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2025 |
| Description: |
Objectives Bictegravir is an integrase strand transfer inhibitor widely prescribed due to its good efficacy and safety profile. Its pharmacokinetic (PK) profile has not been described in real-world settings yet. This study aimed to characterize bictegravir population PK in people with HIV (PWH) and to identify covariates affecting its disposition. Methods Bictegravir concentrations were obtained from PWH as part of a therapeutic drug monitoring (TDM) follow-up performed at the Lausanne University Hospital, Switzerland, between July 2019 and July 2024. Demographic data, clinical data and co-medications were recorded during the routine Swiss HIV Cohort Study (SHCS) visits. A population PK model was developed using a non-linear mixed-effect approach with Monolix®. Results A total of 708 steady-state plasma concentrations from 572 PWH were available for the analysis. A one-compartment model with first-order absorption and elimination best characterized bictegravir PK. Age and body weight were found to significantly affect bictegravir clearance, individuals of 51 years weighing 100 kg showing a 13% increase, and those aged 80 years weighing 70 kg a 11% decrease, relative to an individual weighing 70 kg and aged 51 years. These effects are not deemed clinically significant and do not warrant a clinical intervention. Conclusions Considering the good safety and efficacy profile of bictegravir, routine TDM is of limited value for bictegravir. However, TDM of bictegravir could be beneficial in case of suspected viral resistance or non-adherence, in special subpopulations (i.e. obese individuals and pregnant women), or to monitor drug–drug interactions. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/jac/dkaf297 |
| Availability: |
https://doi.org/10.1093/jac/dkaf297; https://academic.oup.com/jac/article-pdf/80/10/2782/64030895/dkaf297.pdf |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.4D83AE3 |
| Database: |
BASE |